Yuya Atsuta

Yuya Atsuta

Auto-generated profile, based on publicly available information

Yuya Atsuta

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2023 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
MSMasahiro Sakaguchi
Masahiro Sakaguchi
YAYuya Atsuta
Yuya Atsuta
NSNoritaka Sekiya
Noritaka Sekiya
YNYuho Najima
Yuho Najima
KFKazuaki Fukushima
Kazuaki Fukushima
NDNoriko Doki
Noriko Doki
Although antipseudomonal agents are administered in high-risk patients, no reports have focused on the risk of carbapenem-resistant (CR) Pseudomonas aeruginosa bacteraemia in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. We retrospectively studied a cohort of adult allo-HSCT recipients with P. aeruginosa bacteraemia, focusing on a comparison between carbapenem-sensitive (CS) and CR P. aeruginosa after initiating conditioning chemotherapy at our institute between January 2005 and December 2020. The incidence, all-cause 30-d mortality of P. aeruginosa bacteraemia, and risk factors for carbapenem resistance among patients with P. aeruginosa bacteraemia in allo-HSCT recipients were evaluated. Forty-eight patients with P. aeruginosa bacteraemia were included, with an incidence of 3.84/100 recipients (CS = 1.92 vs. CR = 1.92). The all-cause 30-d mortality was significantly higher in CR P. aeruginosa bacteraemia (CS = 4.2% vs. CR = 39.1%; P = 0.003). The factor significantly associated with CR P. aeruginosa bacteraemia was carbapenem use for at least 3 d within 30 d before the onset of bacteraemia (odds ratio = 8.92; 95% confidence interval: 1.35-58.90). Inappropriate antimicrobial selection was significantly more frequent in CR P. aeruginosa bacteraemia (CS = 0% vs. CR = 29.2%; P ˂ 0.009). Empirical combination therapy with reference to antimicrobial susceptibility profiles in each institution should be considered when CR P. aeruginosa bacteraemia is suspected in allo-HSCT recipients based on the risk of carbapenem exposure.

28 October 2026 in Experimental Hematology
Verified
Journal Article
Open access
SAShohei Andoh
Shohei Andoh
YNYaeko Nakajima-Takagi
Yaeko Nakajima-Takagi
SUShun Uemura
Shun Uemura
YAYuya Atsuta
Yuya Atsuta
TFTakanori Fukuta
Takanori Fukuta
Atsushi IwamaAtsushi Iwama
Atsushi Iwama